Objective The inhibition of DPP IV is a validated target in anti-type II diabetic therapy. Existing inhibitors suffer from poor chemical stability or poor selectivity and will be optimised by substituting an amide group for a fluoroolefin group Fields of science medical and health sciencesclinical medicineendocrinologydiabetes Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-4. - Key action Environment and Health Call for proposal Data not available Funding Scheme RGI - Research grants (individual fellowships) Coordinator UNIVERSITAIRE INSTELLING ANTWERPEN - UNIVERSITEIT ANTWERPEN EU contribution No data Address Universiteitsplein 1 2610 WILRIJK (ANTWERPEN) Belgium See on map Total cost No data
